

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

Srdan Verstovsek,¹ Ruben Mesa,² Moshe Talpaz,³ Jean-Jacques Kiladjian,⁴ Claire N. Harrison,⁵ Stephen T. Oh,⁶ Alessandro M. Vannucchi,⁷ Raajit Rampal,⁸ Bart L. Scott,⁹ Sarah A. Buckley,¹⁰ Adam R. Craig,¹⁰ Karisse Roman-Torres¹⁰ and John O. Mascarenhas¹¹

¹MD Anderson Cancer Center, Houston, TX, USA; ²Mayo Clinic, Scottsdale, AZ, USA;

³University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, USA; ⁴Hôpital Saint-Louis, Université Paris Diderot, Paris, France; ⁵Guy's and St Thomas' NHS Foundation Trust, London, UK; ⁶Washington University School of Medicine, St. Louis, MO, USA; ⁷University of Florence, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy; ⁸Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁹Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ¹⁰CTI BioPharma Inc, Seattle, WA, USA and ¹¹Icahn School of Medicine at Mount Sinai, New York, NY, USA

Correspondence:

Srdan Verstovsek
sverstov@mdanderson.org

Received: June 28, 2021.

Accepted: September 15, 2021.

Prepublished: September 23, 2021.

<https://doi.org/10.3324/haematol.2021.279415>

©2022 Ferrata Storti Foundation

Haematologica material is published under a CC BY-NC license 

